其他方法
9.二硝基苯酚。這個化學物是用在工業染料製造和炸藥製作,在職業安全上發現到它對減重有影響,許多兵工廠工人因為特別的原因而痛苦甚至快死亡。結果發現到他們都吸入了DNP灰塵。DNP是一種代謝毒素,它是有毒的然後影響粒線體,不讓粒線體去正常的運作。粒線體就像身體的能量細胞,為葡萄糖和脂肪酸製造能量分子ATP。
存在在DNP環境下,粒線體沒辦法製造ATP然後能量製造減少達到60%,然而能量的需要是因為要去使身體保持穩定運作,因此需要更多的燃料去燃燒提供身體所需。當DNP是極度的濃烈的時候,或許最強的減脂就出現了,這已經不是只是減重了。充滿DNP的地方身體都處於極度氧化的壓力下,導致白內臟和其他問題。健美選手發現DNP很難去忍受所以一般短暫的使用而已。
10.你感興趣的其他品項。許多健美選手使用的產品保證可以減脂。Yohimbine是一種藥物可以阻礙α-2受體,α-2受體阻礙NE在脂肪細胞上的脂肪釋出作用。Captopril是一個抗高血壓的藥物,其阻礙脂肪細胞裡的一個激素活動,然後有可能減少α-2受體。抽脂是一種醫美手術,可以去除特定位置的脂肪。
健美選手會使用極端的手段去減去脂肪。你們可以看到,大部分的方法都有風險而且很多都是違法的也沒有醫生處方。如果你沒有足夠知識的話上面沒有一個方法是你該用的,它們都包含很多代價和風險。如果你選擇使用,那你必須要接受可能會發生的結果和代價。
本篇若有不順請見諒,另外沒有任何藥物或者醫學背景知識請"不要"自行使用文中藥物-Zed
References
1. Llewellyn W. Anabolics 2002. Molecular Nutrition Press, Patchogue, NY, 2002, p 60-62.
2. Prather ID, Brown DE, et al. Clenbuterol: a substitute for anabolic steroids? Med Sci Sports Exerc 1995 Aug;27(8):1118-21.
3. Berman DM, Nicklas BJ, et al. Regional differences in adrenoceptor binding and fat cell lipolysis in obese, postmenopausal women. Metabolism 1998 Apr;47(4):467-73.
4. Mauriege P, DePergola G, et al. Human fat cell beta-adrenergic receptors: beta-agonist-dependent lipolytic responses and characterization of beta-adrenergic binding sites on human fat cell membranes with highly selective beta 1-agonists. J Lipid Res 1988 May;29(5):587-601.
5. Carter WJ, Lynch ME. Comparison of the effects of salbutamol and clenbuterol on skeletal muscle mass and carcass composition in senescent rats. Metabolism 1994 Sep;43(9):1119-25.
6. Rothwell NJ, Stock MJ. Effect of a selective beta 2-adrenergic agonist (clenbuterol) on energy balance and body composition in normal and protein deficient rats. Biosci Rep 1987 Dec;7(12):933-40.
7. Goldstein DR, Dobbs T, et al. Clenbuterol and anabolic steroids: a previously unreported cause of myocardial infarction with normal coronary arteriograms. South Med J 1998 Aug;91(8):780-4.
8. Chodorowski Z, Sein Anand J. Acute poisoning with clenbuterol - a case report. Przegl Lek 1997;54(10):763-4.
9. Van Der Kuy PH, Stegeman A, et al. Falsification of Thai Dianabol. Pharm World Sci 1997 Aug;19:208-9
10. Astrup A, Breum L, et al. Pharmacological and clinical studies of ephedrine and other thermogenic agonists. Obes Res 1995 Nov;3 Suppl 4:537S-540S.
11. Astrup A, Breum L, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord 1992 Apr;16(4):269-77.
12. Anonymous. Adverse events associated with ephedrine-containing products - Texas, December 1993 - September 1995. MMWR Morb Mortal Wkly Rep 1996 Aug 16;45(32):689-93.
13. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000 Dec 21;343(25):1833-8.
14. Bruno A, Nolte KB, et al. Stroke associated with ephedrine use. Neurology 1993 Jul:43(7):1313-6.
15. Molnar D, Torok K, et al. Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents. Int J Obes Relat Metab Disord 2000 Dec;24(12):1573-8.
16. Boozer CN, Nasser JA, et al. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord 2001 Mar;25(3):316-24.
17. Boozer CN, Daly PA, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial.
18. Bross R, Casaburi R, et al. Androgen effects on body composition and muscle function: implications for the use of androgens as anabolic agents in sarcopenic states. Ballieres Clin Endocrinol Metab 1998 Oct;12(3):365-78.
19. Mauras N, Hayes V, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength and adiposity. J Clin Endocrinol Metab 1998 Jun;83(6):1886-92.
20. Munzer T, Harman SM, et al. Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. J Clin Endocrinol Metab 2001 Aug;86(8):3604-10.
21. Lovejoy JC, Bray GA, et al. Oral anabolic steroid treatment, but not parental androgen treatment, decreases abdominal fat in obese, older men. Int J Obes Relat Metab Disord 1995 Sep;19(9):614-24.
22. Llewellyn W. Anabolics 2002. Molecular Nutrition Press, Patchogue, NY, 2002, p 101-4.
23. Yin D, Clarke SD, et al. Transcriptional regulation of fatty acid synthase gene by somatotrophin in 3T3-F442A adipocytes. J Anim Sci 2001 Sep;79(9):2336-45.
24. Asada N, Takahashi Y, et al. Effects of 22K or 20K human growth hormone on lipolysis, leptin production in adipocytes in the presence and absence of human growth hormone binding protein. Horm Res 2000;54(4):203-7.
25. Richelsen B. Action of growth hormone in adipose tissue. Horm Res 1997;48 Suppl 5:105-10.
26. Harant I, Beauville M, et al. Response of fat cells to growth hormone (GH): effect of long term treatment with recombinant human GH in GH-deficient adults. J Clin Endocrinol Metab 1994 Jun;78(6):1392-5.
27. Beauville M, Harant I, et al. Effect of long-term rhGH administration in GH-deficient adults on fat cell epinephrine response. Am J Physiol 1992 Sep;263(3 Pt 1):E467-72.
28. Scacchi M, Pincelli AI, et al. Growth hormone in obesity. Int J Obes Relat Metab Disord 1999 Mar;23(3):260-71.
29. Drent ML, Wever LD, et al. Growth hormone administration in addition to a very low calorie diet and an exercise program in obese subjects. Eur J Endocrinol 1995 May;132(5):565-72.
30. Bhatnagar AS, Brodie AM, et al. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol 2001 Jan-Mar;76(1-5):199-202.
31. Llewellyn W. Anabolics 2002. Molecular Nutrition Press, Patchogue, NY, 2002, p 57.
32. Roselli CE. The effect of anabolic-androgenic steroids on aromatase activity and androgen receptor binding in the rat preoptic area. Brain Res 1998 May 11;792(2):271-6.
33. Pedersen SB, Fuglsig S, et al. Identification of steroid receptors in human adipose tissue. Eur J Clin Invest 1996 Dec;26(12):1051-6.
34. Anderson LA, McTernan PG, et al. The effects of androgens and estrogens on preadipocyte proliferation in human adipose tissue: influence of gender and site. J Clin Endocrinol Metab 2001 Oct;86(10):5045-51.
35. Anderson LA, McTernan PG, et al. The effects of androgens and estrogens on preadipocyte proliferation in human adipose tissue: influence of gender and site. J Clin Endocrinol Metab 2001 Oct;86(10):5045-51.
36. Trunet PF, Mueller P, et al. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab 1993 Aug;77(2):319-23.
37. Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol 2002 Feb;167(2 Pt 1):624-9.
38. Hellstrom L, Wahrenberg H, et al. Catecholamine-induced adipocyte lipolysis in human hyperthyroidism. J Clin Endocrinol Metab 1997 Jan;82(1):159-66.
39. Viguerie N, Millet L, et al. Regulation of human adipocyte gene expression by thyroid hormone. J Clin Endocrinol Metab 2002 Feb;87(2):630-4.
40. Lovejoy JC, Smith SR, et al. A paradigm of experimentally induced mild hyperthyroidism: effects on nitrogen balance, body composition, and energy expenditure in healthy young men. J Clin Endocrinol Metab 1997 Mar;82(3):765-70.
41. Zachwieja JJ, Smith SR, et al. Plasma myostatin-immunoreactive protein is increased after prolonged bed rest with low-dose T3 administration. J Gravit Physiol 1999 Oct;6(2):11-5.
42. Tremblay A, Poehlman ET, et al. Endurance training with constant energy intake in identical twins: changes over time in energy expenditure and related hormones. Metabolism 1997 May;46(5):499-503.
43. Schmidt WD, Hyner GC, et al. The effects of aerobic and anaerobic exercise conditioning on resting metabolic rate and the thermic effect of a meal. Int J Sports Nutr 1994 Dec;4(4):335-46.
44. Ballor DL, Poehlman ET. Resting metabolic rate and coronary-heart-disease risk factors in aerobically and resistance-trained women. Am J Clin Nutr 1992 Dec;56(6):968-74.
45. McCarty MF. Optimizing exercise for fat loss. Med Hypotheses 1995 May;44(5):325-30.
46. Volek JS, Sharman MJ, et al. Body composition and hormonal responses to a carbohydrate-restricted diet [In Process Citation]. Metabolism 2002 Jul;51(7):864-70.
47. Zierath JR, Livingston JN, et al. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signaling through the insulin receptor substrate-1 pathway. Diabetologia 1998 Nov;41(11):1343-54.
48. Moustaid N, Jones BH, et al. Insulin increases lipogenic enzyme activity in human adipocytes in primary culture. J Nutr 1996 Apr;126(4):865-70.
49. Environmental Protection Agency. 2,4-Dinitrophenol 51-28-5, hazard summary. Available through http://www.epa.gov/ttn/uatw/hlthef/dinitrop.html accessed July 2, 2002.
50. Anthony DM, Dickinson K, et al. 2,4-Dinitrophenol: A re-evaluation of metabolic effects both in-vitro and in-vivo. Available through http://www.ebec2000.com/abstracts/056.htm accessed July 2, 2002.
51. Wangsness M. Pharmacologic treatment of obesity. Past, present, and future. Minn Med 2000 Nov;83(11):21-6.
52. Crandall DL, Armellino DC, et al. Angiotensin II receptors in human preadipocytes: role in cell cycle regulation. Endocrinology 1999 Jan;140(1):154-8.
53. Llewellyn W. Anabolics 2002. Molecular Nutrition Press, Patchogue, NY, 2002, p 58.
54. Hunstad JP. Body contouring in the obese patient. Clin Plast Surg 1996 Oct;23(4):647-70.